This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Review -
Recent insights into androgen action on the anatomical and physiological substrate of penile erection
Louis J. G. Gooren1, Farid Saad2,3
1Department of Endocrinology, Andrology Section, Vrije Universiteit Medical Center, 1007 MB Amsterdam, The Netherlands
2Gulf Medical College, Medical University of theUnited Arab Emirates, 2563 Ajman, UAE
3Andrology Department, Schering AG, 13342 Berlin, Germany
Abstract
Erectile response is centrally and peripherally regulated by androgens. The original insights into the mechanisms
of action of androgens were that androgens particularly exert effects on libido and that erections in response to erotic
stimuli were relatively androgen-independent. It was shown that sexual functions in men required androgen levels at
the low end of reference values of testosterone. So it seemed that testosterone was not useful treatment for men with
erectile difficulties, particularly following the advent of the phosphodiesterase type 5 (PDE5) inhibitors. However,
approximately 50 % of those treated with PDE5 inhibitors discontinue their treatment. A number of recent
developments shed new light on testosterone treatment of erectile dysfunction (ED) in aging men. (1) A recent insight is that,
in contrast to younger men, elderly men might require higher levels of testosterone for normal sexual functioning. (2)
Several studies have indicated that PDE5 inhibitors are not always sufficient to restore erectile potency in men, and
that testosterone improves the therapeutical response to PDE5 inhibitors considerably. (3) There is growing insight
that testosterone has profound effects on tissues of the penis involved in the mechanism of erection and that
testosterone deficiency impairs the anatomical and physiological substrate of erectile capacity, reversible upon androgen
replacement. The synthesis of PDE5 is upregulated by androgens, and the arterial inflow into the penis is improved by
giving androgen. The above invites a re-examination of the merits of giving testosterone to aging men with ED. The
beneficial effects of PDE5 inhibitors may only be optimally expressed in a eugonadal environment.
(Asian J Androl 2006 Jan; 8: 3-9)
Keywords: testosterone; erection; corpus cavernosum; phosphodiesterase type 5 inhibitors
Corresponence to: Prof. Louis J. G. Gooren, Department of Endo-crinology, Andrology Section, Vrije Universiteit Medical Center, P.O.
Box 7057, 1007 MB Amsterdam, The Netherlands.
Tel: +31-20-444-0542, Fax: +31-20-444-0502
E-mail: ljg.gooren@vumc.nl
Received 2005-08-30 Accepted 2005-10-24
DOI: 10.1111/j.1745-7262.2006.00105.x
culating testosterone compared with younger men.
The introduction of intracavernous injections of
smooth muscle relaxants, such as papaverine and
prostaglandin E1, was a step forward in the treatment of ED.
This is even more true for the phosphodiesterase type 5
(PDE5) inhibitors. The identification of pathways in the
physiology of erection and the discovery of the
importance of nitric oxide and its downstream effects lay at
the basis of their development [11, 12]. The
introduction of highly efficacious and relatively safe compounds
such as the PDE5 inhibitors has had a profound impact
on the diagnosis and treatment of ED. Patients who had
failed to respond to androgen or other types of treatment
could be successfully treated with PDE 5 inhibitors. The
success of the PDE 5 inhibitors rendered androgens, as
treatment for erectile problems, something of the past.
This seemed rational in view of the assumption that the
primary effects of testosterone were on libido, in other
words, on the central nervous system. Furthermore, it
had become established that less-than-normal
circulating levels of testosterone were sufficient to maintain sexual
functioning; this notion, however, is no longer
tenable [9, 10]. ED, once the domain of the urologist or andrologist,
attempting to define the precise etiology, is now often treated by
first-line physicians, often without much of a diagnostic
work-up. Despite the initial euphoria of a panacea for ED, and the
simplicity and safety of PDE 5 inhibitors, approximately 50 %
of patients discontinue treatment [13, 14]. The reasons
for discontinuation lie for a large part in an incomplete
evaluation of the sexual problem. These may be somatic
factors, such as diabetes mellitus, cardiovascular or
neurological disease and smoking [13, 14], or psychological,
such as unrealistic expectations and emotional aspects
of the sexual relationship [15, 16].
There is a multitude of factors leading to
discontinuation of PDE inhibitors, however, the focus of this paper
is on recent studies that have arrived at the conclusion
that large proportions of men who had failed to respond
to treatment with PDE5 inhibitors appeared to be
testosterone deficient. All studies on ED unanimously agree
that aging is the most significant factor in the etiology of
ED [17]. Over the last 15 years the age-related decline
of circulating testosterone in men has received abundant
attention and its pathophysiological significance is still
hotly debated, although recently consensus on its
approach has been reached by a number of professional
bodies [18]. These two factors together, the age-related
increase in ED and the age-related decline in testosterone
1 Introduction
Since testosterone became pharmaceutically available,
clinicians have been impressed with the powerful effects
it exerts on a man¡¯s sexual functioning. The evidence
for testosterone-induced masculinization of sexual
behavior in men is indeed persuasive. Most of the
information has been collected from androgen
withdrawal/replacement studies of hypogonadal men. The distinction
between sexual interest and erectile function and its
subdivision initially helped considerably in clarifying the role
of androgens in male function [1]. In the first studies,
spontaneous erections, particularly those that occur
during sleep, and probably fantasy-induced erections, were
thought to be exquisitely androgen-dependent, whereas
erections in response to erotic (e.g. visual or tactile) stimuli
were less so [1, 2]. This led to the hypothesis that the
neural circuitries subserving nocturnal erections and
erections in response to sexual arousal were not identical,
explaining their distinctly different androgen dependence.
The original studies [1], however, monitored only penile
circumference but not stiffness, and later observations
showed that androgens do affect penile responses to erotic
stimuli with regard to the duration of response, maximal
degree of rigidity, and speed of detumescence [3, 4], all
significant aspects of androgen effects on sexual functioning.
Nevertheless, this observation did not change the view that in men the principal target of androgen was
sexual interest or appetite [1]. The influence on the penis
was believed to be indirect, through the effects on libido,
rather than direct on penile tissues.
The blood level of testosterone critical for restoring
sexual interest, though varying between individuals,
appeared to be 60 %-70 % of the reference values for
eugonadal men [5-8]. It is of note that these
observations were done in men in a wide age range. Consequently,
it was assumed that in men with erectile dysfunction
(ED) and normal or slightly lower-than-normal
androgen levels, usually an elderly population, additional
testosterone was likely to be of no help, which was in
agreement with the clinical experience of many practitioners.
However, Schiavi and Rehman [9], based on their vast
clinical experience, hypothesized that the threshold for
the biological actions of testosterone might be higher in
elderly men compared to young men. Recently, their
hypothesis was convincingly confirmed experimentally
by Gray et al. [10] showing that in elderly men libido
and erectile function respond only to higher levels of cir
in men, warrant reconsideration of the significance of
testosterone in ED.
Moreover, new research has presented convincing
evidence, mainly in laboratory animals, that testosterone
has profound effects on tissues of the penis involved in
the mechanism of erection and that testosterone
deficiency impairs the anatomical and physiological substrate
of erectile capacity. This study reviewed recent findings
and arrived at the conclusion that the full therapeutical
potential of PDE5 inhibitors can only become manifest
in a eugonadal state, providing some needed nuance to
the earlier beliefs that the effects of testosterone are
primarily and predominantly exerted on libidinous aspects
of the male, and not directly on the penis as well.
2 New insights into the actions of testosterone on
erectile function
We will review recent findings on the following three
topics:
1 The recent results of testosterone replacement
studies showing that restoration of androgen levels to
normal has a beneficial effect on erectile function. These
studies provide no insight into the primary targets of
androgen action, libido or penile structures, but confirm
that normal or near-normal levels of testosterone benefit
erectile function.
2 Failures of restoration of erectile function in men
receiving PDE5 inhibitors due to testosterone deficiency
and the success rates of addition of androgen to the
treatment of men who failed to respond to PDE5 inhibitors
or, vice versa, of addition of PDE5 inhibitors to men
who failed to respond to testosterone treatment.
3 Mechanism of action of androgens on penile
structures related to erectile function. This has been mainly
studied in animals but there is limited evidence obtained
in human studies as well.
2.1 Testosterone replacement in elderly men
The effects of testosterone replacement in younger men
on parameters of sexual functioning have been
convincingly demonstrated, however, studies of the effects in
elderly men are more problematic. These studies have been
reviewed [19, 20]. The review by Morley and Perry [20]
concluded somewhat optimistically that testosterone
supplementation increased libido in 7 of 8 studies and
improved erections in 5 of 6 studies. Recently, in a large
cohort of 406 men (mean age 58 years; total testoster
one = 300 ng/dL) a clear relationship was reported
between restoring serum testosterone to the normal range
and improving certain parameters of sexual functioning,
such as sexual desire, nocturnal erections and frequency
of intercourse [21]. Remarkably, in this study the results
of testosterone administration with a 100 mg gel were
superior to those of 50 mg gel or a
testosterone patch, raising the issue of threshold values of testosterone for sexual
functioning in elderly men. As indicated above, this
assumption was recently substantiated in a study by Gray
et al. [10] showing that the threshold for androgens on
sexual functions in elderly men is higher than in younger
men.
2.2 Combined treatments
Park et al. [13] reported recently that the success
rate of treatment with sildenafil in a cohort of 162 men
(> 60 years) was only 47 %. It could further be
established that among the risk factors predicting a poor
response to sildenafil were smoking and hypogonadism
(plasma testosterone < 3 µg/L). In line with this, Aversa
et al. [22] reported that the circulating levels of free
testosterone, independent of age, positively correlated with
the degree of relaxation of the corporal smooth muscle
cells and the cavernous endothelial cells, giving support
to the potential role of androgens in regulating smooth
muscle function in the penis.
In a later well-designed intervention study
Aversa et al. [23] provided support for this mechanism of
action of testosterone on the erectile tissues of the penis.
They assessed the effects of androgen in 20 patients with
arteriogenic ED (confirmed with dynamic colour duplex
ultrasound) not responding to treatment with sildenafil
100 mg. The patients¡¯ testosterone levels were in the
lower quartile of the normal range. In this
placebo-controlled study, treatment with transdermal testosterone
raised plasma testosterone levels and led to an increase
of arterial inflow into the cavernous tissue and to an
improvement of ED, thus improving the response to
treatment with PDE5 inhibitors. In line with the above, Foresta
et al. [24] have documented that normal plasma
testosterone levels are required for erectile function. In
severely hypogonadal men (plasma testosterone < 2.0 ng/mL) the
nocturnal penile tumescence, ultrasound measurement
of arterial carvernous inflow and visually stimulated
erection in response to sildenafil 50 mg or apomorphine 3 mg
were minimal. The responses to these pharmacological
stimuli normalized after they were given testosterone gel
for six months, evidence of the significant role of
normal levels of testosterone for erectile function. The
notion that testosterone and PDE5 inhibitors have
synergistic effects on nocturnal erections was also confirmed
in men in a laboratory setting by Rochira et
al. [25].
There are clinical studies of large cohorts of patients
to support this notion. Kalinchenko et al. [26] found in a
cohort of 120 men with diabetes mellitus type 2 and ED
that men who had failed to respond to sildenafil 100 mg
had lower plasma testosterone levels than controls. Upon
androgen replacement with oral testosterone undecanoate
restoring testosterone levels to the normal range, 84 of
120 men experienced considerable improvement of their
erectile function. Similar findings were reported by
Shabsigh et al. [27] in their randomized
placebo-controlled double blind study of 75 men with plasma
testosterone levels < 400 ng/dL who had responded poorly
to treatment with sildenafil. Testosterone gel improved
their erectile function compared to placebo, reaching
significance after 4 weeks of treatment, and improved
orgasmic function and overall satisfaction. There were no
significant correlations between plasma testosterone
levels and improvements in sexual function, probably
indicating individual thresholds to the action of testosterone.
Conversely, it could be shown that testosterone
replacement alone is not always satisfactory with regard
to restoring erectile potency. Mulhall et
al. [28] noted in a study of 32 men who were testosterone deficient, and
whose testosterone levels were pharmacologically restored
to normal, that there was an improvement in erectile
function in the first month after reaching normal plasma
testosterone. This subsequently declined in the
following months of the follow-up. In a study of 178 men
with secondary hypogonadism and ED, testosterone levels
were raised following administration of clomiphene, with
beneficial effects on sexual function in 75 % of men. In
the 25 % who experienced no improvement, aging,
diabetes and cardiovascular disease were factors that
emer-ged as significant [29]. That addition of PDE5 inhibitors
may be helpful for such men was demonstrated by Greenstein
et al. [30]. These authors assessed the effects of testosterone replacement in 49 hypogonadal men
with ED. Treatment with testosterone gel led to an
improvement of ED in 31 of the 49 participants. When the
non-responders received sildenafil, the ED of these men
also responded favorably. A number of these studies
su-ggest favorable effects of testosterone administration to
elderly men in addition to PDE5 inhibitors, however, it
has to be remembered that not all of these studies were
blinded and placebo-controlled. Until more definitive data
are available, the interpretation of the results must be
cautious.
2.3 Mechanism of action of androgens on penile
structures
Animal experiments and, to a much more limited degree, human observations suggest that androgens are
necessary to maintain the integrity of the anatomical
structures of the penile erectile tissue and, furthermore, that
androgens are significant in the biochemical mechanisms
subserving penile erection.
In a rat model, Shen et al. [31] demonstrated that
androgen deprivation leads to loss of elastic fibers in the
tunica albuginea and of smooth muscle fibers in the
corpus cavernosum which were replaced by collagenous
fibers in both structures. Similar findings were reported
in the rabbit by Traish et al. [32], noting a reduced
trabecular smooth muscle content, reversible upon
androgen replacement.
Singh et al. [33], analyzing the increase of muscle
mass and decrease of fat mass upon replacement of
testosterone in hypogonadal subjects, found as an
explanation that the mesenchymal pluripotent cells follow a
myogenic lineage or adipogenic lineage, depending on
circulating levels of testosterone. Traish et
al. [34] could demonstrate a similar mechanism in the rabbit with an
accumulation of adipocytes in the subtunical region of the
corpus cavernosum, thus impairing the veno-occlusive
mechanism if testosterone levels are low. This study also
confirmed that androgen deprivation leads to loss of
trabecular smooth muscle and increase of connective tissue fibers.
In another study by Traish et al. [32] it was also
found that intracavernosal pressure, expression of
alpha1-adrenergic receptor and PDE5 activity were clearly
dependent on androgen, which was also the case for
neuronal nitric oxide synthase (nNOS) activity but not for
nNOS protein expression. In a follow-up to this study in
the rabbit model, Traish et al. [35] demonstrated that
even a 50 % reduction in circulating testosterone reduced
intracavernosal blood pressure, which was not enhanced
by treatment with the PDE5 inhibitor vardenafil. NOS and
arginase activities in the corpus cavernosum were not
significantly affected by the reduction in circulating
testosterone. This is in contrast with a study in the
rat [36] where it could be shown that androgen upregulated
neuronal and endothelial NOS, thus facilitating erectile re
sponses upon stimulation of cavernosal nerves. Sato
et al. [37] recently presented data on the powerful effects
of testosterone on the central nervous system (medial
preoptic area) and the peripheral cavernosal nerve of the
rat.
What is known about the human? There are androgen receptors in the human corpus cavernosum [38].
The dependence of PDE5 on androgens in the muscular
and endothelial compartment of the corpus cavernosum
was confirmed in the rat but also in human tissue by
Morelli et al. [39]. Furthermore, Yaman
et al. [40] found in a series of penile biopsies that in men with ED, the
percentage of smooth muscle cells, endothelial cells and
elastic fibers were substantially reduced compared to
controls with normal erectile function. This could be an
indication that structural alterations may play a similar role
in humans as in animal models. Most recently, a case
report by Yassin and Saad [41] showed that venous leak
in a hypogonadal diabetic patient with ED was no longer
manifest after three months of testosterone treatment,
indicating that changes in penile structure may, at least
in part, be reversible.
3 Summary and conclusion
Erectile response in mammals is centrally and
peripherally regulated by androgens. Severe hypogonadism
in men usually results in loss of libido and potency. It
was repeatedly shown that sexual functions in men
required androgen levels below or at the low end of
reference values of testosterone [5-8].
The above considerations, the relative
androgen-independence of erections in response to erotic stimuli and
the relatively low androgen levels required, were reasons
to believe that testosterone was not a useful treatment
for men with erectile difficulties whose testosterone
levels were usually only marginally low.
An even more important element in the disregard of
testosterone as a treatment option was the advent of
intracorporal smooth muscle relaxants (papaverine and
prostaglandin E1), later superseded by the PDE5 inhibitors. When introduced in 1998, the latter were hailed
as the ultimate successful treatment of ED. However,
around 50 % of patients discontinue treatment because of
a lack of success for somatic [13, 14] or psychological
[15] reasons.
There are a number of recent developments which
shed new light on testosterone treatment of ED in aging
men:
1 The recent insight that, in contrast to the results
obtained in younger men [5-8], elderly men might
require higher levels of testosterone for normal sexual
functioning [9, 10]. Actually, reviews of the literature on
testosterone treatment in elderly men on libido and
erectile potency were quite encouraging [19, 20].
2 Several studies have indicated that PDE5
inhibitors are not always sufficient to restore erectile potency
in men [13, 23, 26, 27], and that testosterone improves
the therapeutic response to PDE5 inhibitors
considerably [23, 27].
3 There is growing insight that testosterone has
profound effects on tissues of the penis involved in the
mechanism of erection and that testosterone deficiency
impairs the anatomical and physiological substrate of
erectile capacity, reversible upon androgen replacement.
These data come mainly from animal experimentation,
but a number of studies support their relevance for the
human as well. There are androgen receptors in the
human corpus cavernosum [38].
Lewis and Mills [42], remarking that data on the
testosterone effects on the penis in the human are still limited,
find it reasonable to extrapolate animal dependency of
androgens for molecular activity in the penile tissue to
the human.
The above invites a re-examination of the merits of
testosterone treatment in aging men with ED. It is
becoming clear that the beneficial effects of PDE5
inhibitors are only optimally expressed in a eugonadal
environment [43]. ED is strongly age-related, therefore it is
evident that, inherent in the process of aging, etiology is
multi-factorial, and combinations of drugs might be
needed to restore it. In clinical practice PDE5 inhibitors
will usually be tried first, but it is important to remember
that insufficient success of one type of treatment might
require the addition of the other. There is now
consensus that measurement of serum testosterone is part of
the diagnostic work-up of an elderly man with erectile
difficulties [44], and in cases of proven testosterone
deficiency there is now compelling reason to replace it.
References
1 Bancroft J. Hormones and human sexual behavior. J Sex
Marital Ther 1984; 10: 3-21.
2 Bancroft J, Wu FC. Changes in erectile responsiveness during
androgen replacement therapy. Arch Sex Behav 1983; 12:
59-66.
3 Carani C, Granata AR, Bancroft J, Marrama P. The effects of
testosterone replacement on nocturnal penile tumescence and
rigidity and erectile response to visual erotic stimuli in
hypogonadal men. Psychoneuroendocrinology 1995; 20:
743-53.
4 Granata AR, Rochira V, Lerchl A, Marrama P, Carani C.
Relationship between sleep-related erections and testosterone
levels in men. J Androl 1997; 18: 522-7.
5 Salmimies P, Kockott G, Pirke KM, Vogt HJ, Schill WB.
Effects of testosterone replacement on sexual behavior in
hy-pogonadal men. Arch Sex Behav 1982; 11: 345-53.
6 Gooren LJ. Androgen levels and sex functions in
testosterone-treated hypogonadal men. Arch Sex Behav 1987; 16: 463-73.
7 Buena F, Swerdloff RS, Steiner BS, Lutchmansingh P, Peterson
MA, Pandian MR, et al. Sexual function does not change
when serum testosterone levels are pharmacologically varied
within the normal male range. Fertil Steril 1993; 59: 1118-23.
8 Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D,
Berman N, et al. Testosterone dose-response relationships in
healthy young men. Am J Physiol Endocrinol Metab 2001;
281: E1172-81.
9 Schiavi RC, Rehman J. Sexuality and aging. Urol Clin North
Am 1995; 22: 711-26.
10 Gray PB, Singh AB, Woodhouse LJ, Storer TW, Casaburi R,
Dzekov J, et al. Dose-dependent effects of testosterone on
sexual function, mood, and visuospatial cognition in older men.
J Clin Endocrinol Metab 2005; 90: 3838-46.
11 Huang XB, Xiong CL, Yu CG, Zhou JL, Shen JY. Effect of
sildenafil citrate on penile erection of rhesus macaques. Asian
J Androl 2004; 6: 233-5.
12 Park JY, Son H, Kim SW, Paick JS. Potentiation of
apomorphine effect on sildenafil-induced penile erection in conscious
rabbits. Asian J Androl 2004; 6: 205-9.
13 Park K, Ku JH, Kim SW, Paick JS. Risk factors in predicting
a poor response to sildenafil citrate in elderly men with
erectile dysfunction. BJU Int 2005; 95: 366-70.
14 de Tejada IS. Therapeutic strategies for optimizing PDE-5
inhibitor therapy in patients with erectile dysfunction
considered difficult or challenging to treat. Int J Impot Res 2004;16
Suppl 1: S40-2.
15 Althof SE. When an erection alone is not
enough: biopsy-chosocial obstacles to lovemaking. Int J Impot Res 2002; 14
Suppl 1: S99-104.
16 Klotz T, Mathers M, Klotz R, Sommer F. Why do patients
with erectile dysfunction abandon effective therapy with
sildenafil (Viagra)? Int J Impot Res 2005; 17: 2-4.
17 Araujo AB, O'Donnell AB, Brambilla DJ, Simpson WB,
Longcope C, Matsumoto AM, et al. Prevalence and incidence
of androgen deficiency in middle-aged and older men:
estimates from the Massachusetts Male Aging Study. J Clin
Endocrinol Metab 2004; 89: 5920-6.
18 Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman
JM, Legros JJ, et al. Investigation, treatment and monitoring
of late-onset hypogonadism in males. ISA, ISSAM, and EAU
recommendations. Eur Urol 2005; 48: 1-4.
19 Jain P, Rademaker AW, McVary KT. Testosterone supple
mentation for erectile dysfunction: results of a meta-analysis.
J Urol 2000; 164: 371-5.
20 Morley JE, Perry HM 3rd. Androgen treatment of male
hypogonadism in older males. J Steroid Biochem Mol Biol 2003;
85: 367-73.
21 Seftel AD, Mack RJ, Secrest AR, Smith TM. Restorative
increases in serum testosterone levels are significantly
correlated to improvements in sexual functioning. J Androl 2004;
25: 963-72.
22 Aversa A, Isidori AM, De Martino MU, Caprio M, Fabbrini
E, Rocchietti-March M, et al. Androgens and penile erection:
evidence for a direct relationship between free testosterone
and cavernous vasodilation in men with erectile dysfunction.
Clin Endocrinol (Oxf) 2000; 53: 517-22.
23 Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri, A. Androgens
improve cavernous vasodilation and response to sildenafil in
patients with erectile dysfunction. Clin Endocrinol (Oxf) 2003;
58: 632-8.
24 Foresta C, Caretta N, Rossato M, Garolla A, Ferlin A. Role of
androgens in erectile function. J Urol 2004; 171: 2358-62;
quiz 2435.
25 Rochira V, Madeo B, Zirilli L, Diazzi C, Granata R, Baliestrieri
A, et al. Testosterone and sildenafil in hypogonadal men:
evidence for a synergistic effect. Endocrine Society Meeting
Abstract; 2005 June 4-7; San Diego, CA, USA. CA: Endocrine
Society; 2005. p1-551.
26 Kalinchenko SY, Kozlov GI, Gontcharov NP, Katsiya GV.
Oral testosterone undecanoate reverses erectile dysfunction
associated with diabetes mellitus in patients failing on sildenafil
citrate therapy alone. Aging Male 2003; 6: 94-9.
27 Shabsigh R. Testosterone therapy in erectile dysfunction.
Aging Male 2004; 7: 312-8.
28 Mulhall JP, Valenzuela R, Aviv N, Parker M. Effect of
testosterone supplementation on sexual function in hypogonadal
men with erectile dysfunction. Urology 2004; 63: 348-53.
29 Guay AT, Jacobson J, Perez JB, Hodge MB, Velasquez E.
Clomiphene increases free testosterone levels in men with
both secondary hypogonadism and erectile dysfunction: who
does and does not benefit? Int J Impot Res 2003; 15: 156-65.
30 Greenstein A, Mabjeesh NJ, Sofer M, Kaver I, Matzkin H,
Chen J. Does sildenafil combined with testosterone gel
improve erectile dysfunction in hypogonadal men in whom
testosterone supplement therapy alone failed? J Urol 2005; 173:
530-2.
31 Shen ZJ, Zhou XL, Lu YL, Chen ZD. Effect of androgen
deprivation on penile ultrastructure. Asian J Androl 2003; 5:
33-6.
32 Traish AM, Traish AM, Park K, Dhir V, Kim NN, Moreland
RB, et al. Effects of castration and androgen replacement on
erectile function in a rabbit model. Endocrinology 1999; 140:
1861-8.
33 Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin
S. Androgens stimulate myogenic differentiation and inhibit
adipogenesis in C3H 10T1/2 pluripotent cells through an
androgen receptor-mediated pathway. Endocrinology 2003; 144:
5081-8.
34 Traish AM, Toselli P, Jeong SJ, Kim NN. Adipocyte
accumulation in penile corpus cavernosum of the orchiectomized
rabbit: a potential mechanism for veno-occlusive dysfunction
in androgen deficiency. J Androl 2005; 26: 242-8.
35 Traish AM, Munarriz R, O'Connell L, Choi S, Kim SW, Kim
NN, et al. Effects of medical or surgical castration on erectile
function in an animal model. J Androl 2003; 24: 381-7.
36 Marin R, Escrig A, Abreu P, Mas M. Androgen-dependent
nitric oxide release in rat penis correlates with levels of
constitutive nitric oxide synthase isoenzymes. Biol Reprod 1999;
61: 1012-6.
37 Sato Y, Suzuki N, Hisasue S, Kato R, Suzuki K, Tsukamoto T.
Direct effects of testosterone on intracavernosous pressure
elicited by electrical stimulation of the MPOA in male rats
[Abstract]. J Urol 2005; 173: 272.
38 Schultheiss D, Badalyan R, Pilatz A, Gabouev AI, Schlote N,
Wefer J, et al. Androgen and estrogen receptors in the human
corpus cavernosum penis: immunohistochemical and cell
culture results. World J Urol 2003; 21: 320-4.
39 Morelli A Filippi S, Mancina R, Luconi M, Vignozzi L, Marini
M, et al. Androgens regulate phosphodiesterase type 5
expression and functional activity in corpora cavernosa.
Endocrinology 2004; 145: 2253-63.
40 Yaman O, Yilmaz E, Bozlu M, Anafarta K. Alterations of
intracorporeal structures in patients with erectile dysfunction.
Urol Int 2003; 71: 87-90.
41 Yassin ASF. Changes in penile cavernosography and venous
leakage under testosterone treatment in hypogonadal patients
with ED. Case report [abstract]. Int J Androl 2005; 28: 53.
42 Lewis RW, Mills TM. Effect of androgens on penile tissue.
Endocrine 2004; 23: 101-5.
43 Frajese GV, Pozzi F. New achievement and novel therapeutic
applications of PDE5 inhibitors in older males. J Endocrinol
Invest 2005; 28: 45-50.
44 Morales A. Testosterone treatment for the aging man: the
controversy. Curr Urol Rep 2004; 5: 472-7.
|